Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer

2.1 Selpercatinib (Retsevmo, Eli Lilly) is indicated for 'the treatment of adults with advanced RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor'.

2.2 Selpercatinib is also recommended with managed access for previously treated RET fusion-positive advanced NSCLC (see NICE's technology appraisal guidance 760).

2.3 The dosage schedule is available in the summary of product characteristics for selpercatinib.

2.4 The list price for 56 capsules of selpercatinib (80 mg) is £4,368 (excluding VAT; BNF online, accessed February 2023). The company's estimated cost for a 28‑day cycle of selpercatinib is £8,736.00.

2.5 The company has a commercial arrangement. This makes selpercatinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.